Intrapleural transplantation of allogeneic pancreatic islets achieves glycemic control in a diabetic non-human primate.
Intrapleural transplantation of allogeneic pancreatic islets achieves glycemic control in a diabetic non-human primate.
复制标题
DOI：
10.1111/ajt.16875
复制
发表时间：
2022-03
期刊：
影响因子：
--
通讯作者：
Markmann JF
中科院分区：
文献类型：
--
作者：
Lei J;Zhang A;Deng H;Yang Z;Peters CW;Lee KM;Wang Z;Rosales IA;Rickert CG;Markmann JF
临床胰岛移植几乎完全依赖于胰岛的门静脉内给药，因为它是在人类受体中实现强大移植功能的唯一一致方法。然而，这种方法遭受来自有效的立即血液介导的炎症反应（IBMIR）和缺氧环境的胰岛质量的显著损失。为了避免这些负面方面的门户网站，我们探索了一种替代方法，其中同种异体胰岛移植到胸膜内空间的NHP，治疗与免疫抑制方案先前报道，以确保常规的生存和耐受性，同种异体胰岛NHP。在>90天的计划研究期内实现了稳健的血糖控制和移植物存活。我们的观察结果表明，胸膜内空间提供了一个有吸引力的场所胰岛移植，由于其较高的氧分压，能够容纳大的移植组织体积，并缺乏IBMIR介导的胰岛损伤。我们的初步研究结果表明，胸膜腔内作为临床胰岛移植治疗1型糖尿病的替代部位的前景。
Clinical islet transplantation has relied almost exclusively on intraportal administration of pancreatic islets, as it has been the only consistent approach to achieve robust graft function in human recipients. However, this approach suffers from significant loss of islet mass from a potent immediate blood mediated inflammatory response (IBMIR) and a hypoxic environment. To avoid these negative aspects of the portal site, we explored an alternative approach in which allogeneic islets were transplanted into the intrapleural space of an NHP, treated with an immunosuppression regimen previously reported to secure routine survival and tolerance to allogeneic islets in NHP. Robust glycemic control and graft survival were achieved for the planned study period of >90 days. Our observations suggest the intrapleural space provides an attractive locale for islet transplantation due to its higher oxygen tension, ability to accommodate large transplant tissue volumes, and a lack of IBMIR-mediated islet damage. Our preliminary results reveal the promise of the intrapleural space as an alternative site for clinical islet transplantation in the treatment of type 1 diabetes.
登录
查看更多内容
影响因子：
7.7
作者：
Henriksnäs J;Lau J;Zang G;Berggren PO;Köhler M;Carlsson PO
通讯作者：
Carlsson PO
影响因子：
20.8
作者：
Yu M;Agarwal D;Korutla L;May CL;Wang W;Griffith NN;Hering BJ;Kaestner KH;Velazquez OC;Markmann JF;Vallabhajosyula P;Liu C;Naji A
通讯作者：
Naji A
影响因子：
7.7
作者：
Johansson, H;Lukinius, A;Nilsson, B
通讯作者：
Nilsson, B
影响因子：
7.7
作者：
Harlan DM;Kenyon NS;Korsgren O;Roep BO;Immunology of Diabetes Society
通讯作者：
Immunology of Diabetes Society
影响因子：
0.9
作者：
Caiazzo, R.;Gmyr, V.;Pattou, F.
通讯作者：
Pattou, F.